Paul M. Peloso, MD, joined COUR in 2024 as Chief Medical Officer where he leads the company’s clinical development programs.
Prior to joining COUR, Dr. Peloso served as Chief Medical Officer for ACELYRIN, Inc., a biopharma company focused on providing life-changing new treatment options for patients by employing a strategy of identifying, acquiring and accelerating development and commercialization of promising drug candidates. While at ACELYRIN, Dr. Peloso was responsible for global clinical development of the company’s pipeline of products, with an initial focus in immunology.
Before ACELYRIN, Dr. Peloso was vice president and therapeutic head for rheumatology of Horizon Therapeutics, where he was responsible for advancing the company’s pipeline of first-in-class rare disease medicines including, notably KRYSTEXXA® until its acquisition by Amgen in 2023. Prior to this role, Dr. Peloso served as group medical director for both AbbVie and Merck, where he leveraged his extensive experience in biologics, small molecules, and medical devices.
Among Dr. Peloso’s global clinical and regulatory achievements across his career, he helped develop and ultimately secure approvals for ORILISSA® (elagolix), ILUMYA™ (tildrakizumab), Arcoxia® (etoricoxib), and Enbrel® (etanercept). Dr. Peloso has also led a broad range of successful filings in numerous therapeutic areas that have led to approvals by the U.S. Food and Drug Administration, European Medicines Agency and in the Asian and Latin American markets.
Prior to entering the industry, Dr. Peloso was in academic practice in rheumatology in the U.S. and Canada. He holds two bachelor’s degrees, one in biochemistry and another in sociology, from McMaster University and earned his medical degree from the University of Calgary before training in rheumatology and epidemiology.